E-cadherin mediates the aggregation of breast cancer cells induced by tamoxifen and epidermal growth factor

Breast Cancer Research and Treatment

Volumn 121, Issue 1, 2010, Pages 79-89

  Mauro, Loredana ^a   Pellegrino, Michele ^a   Lappano, Rosamaria ^a   Vivacqua, Adele ^a   Giordano, Francesca ^a   Palma, Maria Grazia ^a   Andò, Sebastiano ^a   Maggiolini, Marcello ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Breast cancer; E cadherin; EGF; Tamoxifen; Three dimensional cultures

Indexed keywords

4 HYDROXYTAMOXIFEN; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; TAMOXIFEN; TRANSCRIPTION FACTOR SP1; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL AGGREGATION; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CADHERINS; CELL ADHESION; CELL AGGREGATION; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 77951299090     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0456-4     Document Type: Article

References (63)

1. C Smigal A Jemal E Ward, et al. 2006 Trends in breast cancer by race, ethnicity: update 2006 CA Cancer J Clin 56 3 168 183 10.3322/canjclin.56.3.168 16737949
2. F Bray P McCarron DM Parkin 2004 The changing global patterns of female breast cancer incidence and mortality Breast Cancer Res 6 229 239 10.1186/bcr932 15535852 (Pubitemid 39440251)
3. A Jemal A Thomas T Murray, et al. 2002 Cancer statistics, 2002 CA Cancer J Clin 52 23 47 10.3322/canjclin.52.1.23 11814064
4. Y Ishii S Waxman D Germain 2008 Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3 Cancer Res 68 3 852 860 10.1158/0008-5472.CAN-07-2879 1:CAS:528:DC%2BD1cXhtlygt7g%3D 18245487 (Pubitemid 351206763)
5. V Giguere A Tremblay GB Tremblay 1998 Estrogen receptor beta: re-evaluation of estrogen and antiestrogen signaling Steroids 63 5-6 335 339 10.1016/S0039-128X(98)00024-5 1:CAS:528:DyaK1cXjs1ehu7s%3D 9618797 (Pubitemid 28265672)
6. NJ Mc Kenna BW O' Malley 2002 Combinatorial control of gene expression by nuclear receptors and coregulators Cell 108 465 474 10.1016/S0092-8674(02) 00641-4 1:CAS:528:DC%2BD38XhvF2jsro%3D (Pubitemid 34260872)
7. B Cenni D Picard 1999 Ligand-independent activation of steroid receptors: new roles for old players Trends Endocrinol Metab 10 41 46 10.1016/S1043- 2760(98)00121-0 1:CAS:528:DyaK1MXhvVylt78%3D 10322393 (Pubitemid 29287821)
8. NL Weigel Y Zhang 1998 Ligand-independent activation of steroid hormone receptors J Mol Med 76 469 479 10.1007/s001090050241 1:CAS:528: DyaK1cXksVSktL8%3D 9660165 (Pubitemid 28261256)
9. G Bunone PA Briand RJ Miksicek, et al. 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation EMBO J 15 9 2174 2183 1:CAS:528:DyaK28XjtFyjtrs%3D 8641283
10. W Feng P Webb P Nguyen, et al. 2001 Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway Mol Endocrinol 15 32 45 10.1210/me.15.1.32 1:CAS:528:DC%2BD3MXktVKnug%3D%3D 11145737 (Pubitemid 32156039)
11. RM Lavinsky K Jepsen T Heinzel, et al. 1998 Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes Proc Natl Acad Sci USA 95 2920 2925 10.1073/pnas.95.6.2920 1:CAS:528:DyaK1cXitV2is7s%3D 9501191 (Pubitemid 28135830)
12. H Lee F Jiang Q Wang, et al. 2000 MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells Mol Endocrinol 14 1882 1896 10.1210/me.14.11.1882 1:CAS:528:DC%2BD3cXnvVOrsLw%3D 11075819
13. IA Jaiyesimi AU Buzdar DA Decker, et al. 1995 Use of tamoxifen for breast cancer: twenty-eight years later J Clin Oncol 13 513 529 1:STN:280: DyaK2M7kslSnsw%3D%3D 7844613
14. S Massarweh CK Osborne CJ Creighton, et al. 2008 Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function Cancer Res 68 3 826 833 10.1158/0008-5472.CAN-07-2707 1:CAS:528:DC%2BD1cXhtlygtrY%3D 18245484 (Pubitemid 351206760)
15. RB Lichtner 2003 Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies Biomed Pharmacother 57 10 447 451 10.1016/j.biopha.2003.09.006 1:CAS:528:DC%2BD3sXpt1Whs7s%3D 14637387 (Pubitemid 37452413)
16. H Kim WJ Muller 1999 The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis Exp Cell Res 253 1 78 87 10.1006/excr.1999.4706 1:CAS:528:DyaK1MXnsF2itL8%3D 10579913
17. B Vanhaesebroeck DR Alessi 2000 PI3 K-PDK1 connection: more than just a road to PKB Biochem J 346 561 576 10.1042/0264-6021:3460561 1:CAS:528: DC%2BD3cXit1Kku78%3D 10698680 (Pubitemid 30171014)
18. LC Cantley 2002 The phosphoinositide 3-kinase pathway Science 296 1655 1657 10.1126/science.296.5573.1655 1:CAS:528:DC%2BD38XktlChu7s%3D 12040186 (Pubitemid 34579158)
19. G Pearson F Robinson T Beers Gibson, et al. 2001 Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions Endocr Rev 22 153 183 10.1210/er.22.2.153 1:CAS:528:DC%2BD3MXjsFSntL4%3D 11294822 (Pubitemid 32458157)
20. C Peyssonnaux A Eychene 2001 The Raf/MEK/ERK pathway: new concepts of activation Biol Cell 93 53 62 10.1016/S0248-4900(01)01125-X 1:CAS:528: DC%2BD3MXptVOju7s%3D 11730323 (Pubitemid 33040860)
21. JM Kyriakis J Avruch 2001 Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation Physiol Rev 81 807 869 1:CAS:528:DC%2BD3MXislCrsb8%3D 11274345
22. R Schiff S Massarweh J Shou, et al. 2003 Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response Clin Cancer Res 9 447S 454S 1:CAS:528:DC%2BD3sXnt1yjsw%3D%3D 12538499 (Pubitemid 36105786)
23. RJ Santen RX Song R McPherson, et al. 2002 The role of mitogen-activated protein (MAP) kinase in breast cancer J Steroid Biochem Mol Biol 80 239 256 10.1016/S0960-0760(01)00189-3 1:CAS:528:DC%2BD38XhvVCiurw%3D 11897507 (Pubitemid 34233743)
24. F Vignon MM Bouton H Rochefort 1987 Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens Biochem Biophys Res Commun 146 1502 1508 10.1016/0006-291X(87)90819-9 1:CAS:528:DyaL2sXlt1OnsLk%3D 3304294 (Pubitemid 17153311)
25. DM Ignar-Trowbridge KG Nelson MC Bidwell, et al. 1992 Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor Proc Natl Acad Sci U S A 89 4658 4662 10.1073/pnas.89.10.4658 1:CAS:528:DyaK38XktVWhtrc%3D 1584801
26. S Hewitt JC Harrell KS Korach 2005 Lessons in estrogen biology from knockout and transgenic animals Annu Rev Physiol 67 285 308 10.1146/annurev. physiol.67.040403.115914 1:CAS:528:DC%2BD2MXjsFeksr4%3D 15709960 (Pubitemid 40404493)
27. M Takeichi 1991 Cadherin cell adhesion receptors as a morphogenetic regulator Science 251 1451 1455 10.1126/science.2006419 1:CAS:528: DyaK3MXhvVSnsbg%3D 2006419
28. M Takeichi 1995 Morphogenetic roles of classic cadherins Curr Opin Cell Biol 7 619 627 10.1016/0955-0674(95)80102-2 1:CAS:528:DyaK2MXosVKnsr8%3D 8573335
29. AK Perl P Wilgenbus U Dahl, et al. 1998 A causal role for E-cadherin in the transition from adenoma to carcinoma Nature 392 190 193 10.1038/32433 1:CAS:528:DyaK1cXhvFelsL4%3D 9515965 (Pubitemid 28162793)
30. J Behrens MM Mareel FM Van Roy, et al. 1989 Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin mediated cell-cell adhesion J Cell Biol 108 2435 2447 10.1083/jcb.108.6.2435 1:CAS:528:DyaL1MXit12gt7g%3D 2661563
31. UH Frixen J Behrens M Sachs, et al. 1991 E-cadherin mediated cell-cell adhesion prevents invasiveness of human carcinoma cells J Cell Biol 113 173 185 10.1083/jcb.113.1.173 1:CAS:528:DyaK3MXhvVejur8%3D 2007622
32. K Vleminckx L Vakaet Jr M Mareel, et al. 1991 Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role Cell 66 107 119 10.1016/0092-8674(91)90143-M 1:CAS:528:DyaK3MXlsFKisL0%3D 2070412
33. S Dorudi JP Sheffield R Poulsom, et al. 1993 E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study Am J Pathol 142 981 986 1:STN:280:DyaK3s3jsF2lsg%3D%3D 7682766
34. D Mbalaviele CR Dunstan A Sasaki, et al. 1996 E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model Cancer Res 56 4063 4070 1:CAS:528:DyaK28XltlSntL4%3D 8752180
35. L Mauro S Catalano G Bossi, et al. 2007 Evidences that leptin upregulates E-cadherin expression in breast cancer: effects on tumor growth and progression Cancer Res 67 7 3412 3421 10.1158/0008-5472.CAN-06-2890 1:CAS:528: DC%2BD2sXksVGksb0%3D 17409452 (Pubitemid 46724882)
36. CN Tsai CL Tsai KP Tse, et al. 2002 The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases Proc Natl Acad Sci USA 99 10084 10089 10.1073/pnas.152059399 1:CAS:528:DC%2BD38XlslKgtL0%3D 12110730 (Pubitemid 34831176)
37. M Maggiolini O Donzè D Picard 1999 A non-radioactive method for inexpensive quantitative RT-PCR J Biol Chem 380 695 697 10.1515/BC.1999.086 1:CAS:528:DyaK1MXksVWgurk%3D (Pubitemid 29322360)
38. C Morelli C Garofalo D Sisci, et al. 2004 Nuclear insulin receptor substrate 1 interacts with estrogen receptor a at ERE promoters Oncogene 23 7517 7526 10.1038/sj.onc.1208014 1:CAS:528:DC%2BD2cXnvFGkur8%3D 15318176 (Pubitemid 39389693)
39. V Dangles F Femenia V Laine, et al. 1997 Two- and three-dimensional cell structures govern epidermal growth factor survival function in human bladder carcinoma cell lines Cancer Res 57 3360 3364 1:CAS:528:DyaK2sXls1Shtb0%3D 9269996
40. LA Kunz-Schughart M Kreutz R Knuechel 1998 Multicellular spheroids: a three-dimensional in vitro culture system to study tumour biology Int J Exp Pathol 79 1 23 10.1046/j.1365-2613.1998.00051.x 1:STN:280:DyaK1c3ns1Crtw%3D%3D 9614346 (Pubitemid 28137705)
41. MT Santini G Rainaldi 1999 Three-dimensional spheroid model in tumor biology Pathobiology 67 148 157 10.1159/000028065 1:CAS:528:DyaK1MXktlKls7s%3D 10394136 (Pubitemid 29304376)
42. S Massarweh R Schiff 2006 Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk Endocr Relat Cancer 13 1 S15 S24 10.1677/erc.1.01273 1:CAS:528:DC%2BD2sXivF2mtLk%3D 17259554 (Pubitemid 46219245)
43. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 1998 Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1451 1467 10.1016/S0140-6736(97)11423-4 (Pubitemid 28227036)
44. G Arpino L Wiechmann CK Osborne, et al. 2008 Cross-talk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance Endocrine Rev 29 217 233 10.1210/er.2006-0045 1:CAS:528:DC%2BD1cXltlOhsrk%3D (Pubitemid 351519691)
45. MH Herynk SAW Fuqua 2004 Estrogen receptor mutations in human disease Endocrine Rev 25 6 869 898 10.1210/er.2003-0010 1:CAS:528:DC%2BD2MXjslWnsA%3D%3D (Pubitemid 39657771)
46. B Long BM McKibben M Lynch, et al. 1992 Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line Br J Cancer 65 6 865 869 1:CAS:528:DyaK38Xlt1Ggtrs%3D 1616857
47. RI Nicholson RA McClelland JM Gee, et al. 1994 Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy Breast Cancer Res Treat 29 117 125 10.1007/BF00666187 1:STN:280:DyaK2c3ovFOlug%3D%3D 7912565
48. CK Osborne J Shou S Massarweh, et al. 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer Clin Cancer Res 11 865s 865s 870s 1:CAS:528:DC%2BD2MXislWgu7k%3D 15701879 (Pubitemid 40111098)
49. P Joel J Smith T Sturgill, et al. 1998 pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167 Mol Cell Biol 18 1978 1984 1:CAS:528:DyaK1cXitFeqtrY%3D 9528769
50. JM Gee JF Robertson E Gutteridge, et al. 2005 Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer Endocr Relat Cancer 12 S99 S111 10.1677/erc.1.01005 1:CAS:528:DC%2BD2MXhtFyitb3N 16113104 (Pubitemid 41395417)
51. J Shou S Massarweh CK Osborne, et al. 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96 926 935 1:CAS:528:DC%2BD2cXltVWmtLY%3D 15199112
52. R Michalides A Griekspoor A Balkenende, et al. 2004 Tamoxifen resistance by a conformational arrest of the estrogen receptor a after PKA activation in breast cancer Cancer Cell Int 5 597 605 10.1016/j.ccr.2004.05.016 1:CAS:528:DC%2BD2cXltlGgsLo%3D (Pubitemid 38748921)
53. RI Nicholson RA McClelland P Finlay, et al. 1993 Relationship between EGF-R, c-erbB2 protein expression and Ki67immunostaining in breast cancer and hormone sensitivity Eur J Cancer 29A 1018 1023 10.1016/S0959-8049(05)80215-1 1:STN:280:DyaK3s3ntVyjtw%3D%3D 8098946
54. TT van Agthoven TL van Agthoven H Portengen, et al. 1992 Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells Cancer Res 52 5082 5088 1516065
55. CC Benz GK Scott JC Sarup, et al. 2000 Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7cells transfected with HER2/neu Breast Cancer Res Treat 24 85 95 10.1007/BF01961241
56. P Reddy L Lui C Ren, et al. 2005 Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells Mol Endocrinol 19 2564 2578 10.1210/me.2004-0342 1:CAS:528:DC%2BD2MXhtFWju7jO 15928314 (Pubitemid 41362669)
57. MS Steinberg PM McNutt 1999 Cadherins and their connections: adhesion junctions have broader functions Curr Opin Cell Biol 11 554 560 10.1016/S0955-0674(99)00027-7 1:CAS:528:DyaK1MXmslajtbo%3D 10508659 (Pubitemid 29460395)
58. SM Siitonen JT Kononen HJ Helin, et al. 1996 Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer Am J Clin Pathol 105 394 402 1:STN:280:DyaK287otFSlug%3D%3D 8604681
59. C Charpin S Garcia P Bonnier, et al. 1998 Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival Am J Clin Pathol 109 431 438 1:STN:280: DyaK1c7psFSktg%3D%3D 9535397
60. R Heimann F Lan R McBride, et al. 2000 Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin Cancer Res 60 298 304 1:CAS:528:DC%2BD3cXhtVahs7g%3D 10667580
61. KS Asgeirsson JG Jonasson L Tryggvadottir, et al. 2000 Altered expression of E-cadherin in breast cancer: patterns, mechanisms and clinical significance Eur J Cancer 36 1098 1106 10.1016/S0959-8049(00)00062-9 1:CAS:528: DC%2BD3cXjvFGqsrk%3D 10854942 (Pubitemid 30330907)
62. P Lipponen E Saarelainen S Aaltomaa, et al. 1994 Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer J Pathol 174 101 109 10.1002/path.1711740206 1:STN:280:DyaK2M%2FlsVOmsA%3D%3D 7965405 (Pubitemid 24318453)
63. DS Tan HW Potts AC Leong, et al. 1999 The biological and prognostic significance of cell polarity and E-cadherin in grade I infiltrating ductal carcinoma of the breast J Pathol 189 20 22 10.1002/(SICI)1096-9896(199909)189: 1<20::AID-PATH394>3.0.CO;2-2 1:STN:280:DyaK1Mzot1Cjtg%3D%3D 10451483 (Pubitemid 29406814)